Literature DB >> 1822225

HPLC determination of doxorubicin, doxorubicinol and four aglycone metabolites in plasma of AIDS patients.

J H Beijnen1, P L Meenhorst, R van Gijn, M Fromme, H Rosing, W J Underberg.   

Abstract

A high-performance liquid chromatographic (HPLC) assay has been developed for the determination of the anticancer drug doxorubicin and the metabolites doxorubicinol, doxorubicinone, 7-deoxydoxorubicinone, doxorubicinolone and 7-deoxydoxorubicinolone in plasma of AIDS patients. Samples can be heated at 60 degrees C for 30 min to inactivate the human immunodeficiency virus. The sample pre-treatment involves a liquid-liquid extraction of the buffered plasma sample (pH 9) with a chloroform-1-propanol (4:1, v/v) mixture. The chromatographic analysis is performed on a Lichrosorb RP-8 (5 microns) column and by isocratic elution with a mobile phase of acetonitriletetrahydrofuran-phosphate buffer (pH 2.2) (800:5:200, w/w/w) with fluorescence detection (excitation wavelength: 460 nm; emission wavelength: 550 nm). The proposed method has been validated and, subsequently, implemented in a pharmacokinetic study of doxorubicin in AIDS patients with Kaposi's sarcoma who are treated with the combination regimen doxorubicin, vincristine and bleomycin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1822225     DOI: 10.1016/0731-7085(91)80036-9

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  7 in total

1.  High concentration of Daunorubicin and Daunorubicinol in human malignant astrocytomas after systemic administration of liposomal Daunorubicin.

Authors:  K W Albrecht; P C de Witt Hamer; S Leenstra; P J Bakker; J H Beijnen; D Troost; P Kaaijk; A D Bosch
Journal:  J Neurooncol       Date:  2001-07       Impact factor: 4.130

2.  Biodegradable intraprostatic doxorubicin implants.

Authors:  Ronnie Ortiz; Jessie L-S Au; Ze Lu; Yuebo Gan; M Guillaume Wientjes
Journal:  AAPS J       Date:  2007-06-29       Impact factor: 4.009

3.  Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC).

Authors:  H Rosing; W W ten Bokkel Huinink; R van Gijn; R F Rombouts; A Bult; J H Beijnen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Jan-Mar       Impact factor: 2.569

4.  HPLC Method Development for Quantification of Doxorubicin in Cell Culture and Placental Perfusion Media.

Authors:  Mansi Shah; Luke Bourner; Shariq Ali; Sanaalarab Al-Enazy; Menatallah M Youssef; Morgan Fisler; Erik Rytting
Journal:  Separations       Date:  2018-01-24

5.  Liquid Chromatography-Tandem Mass Spectrometry for the Simultaneous Determination of Doxorubicin and its Metabolites Doxorubicinol, Doxorubicinone, Doxorubicinolone, and 7-Deoxydoxorubicinone in Mouse Plasma.

Authors:  Won-Gu Choi; Dong Kyun Kim; Yongho Shin; Ria Park; Yong-Yeon Cho; Joo Young Lee; Han Chang Kang; Hye Suk Lee
Journal:  Molecules       Date:  2020-03-10       Impact factor: 4.411

6.  A precision medicine approach to defining the impact of doxorubicin on the bioenergetic-metabolite interactome in human platelets.

Authors:  Matthew Ryan Smith; Balu K Chacko; Michelle S Johnson; Gloria A Benavides; Karan Uppal; Young-Mi Go; Dean P Jones; Victor M Darley-Usmar
Journal:  Redox Biol       Date:  2019-09-07       Impact factor: 11.799

7.  Bioanalysis of doxorubicin aglycone metabolites in human plasma samples-implications for doxorubicin drug monitoring.

Authors:  Christian Siebel; Claudia Lanvers-Kaminsky; Gudrun Würthwein; Georg Hempel; Joachim Boos
Journal:  Sci Rep       Date:  2020-10-29       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.